Study of Tozuleristide and the Canvas Imaging System in Pediatric Subjects With CNS Tumors Undergoing Surgery

Model scores of the 29,894 trials active now.

Model score 27% for any early termination, 3% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 34% of the time (35 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2022-06-13. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: tumorsubjectstherapysurgerychild
  Phrases that lowered it: 28intervaldaysleadscreening
• Accepts healthy volunteers: No (raises risk) · Who can join
• Primary purpose: other (lowers risk) · Design
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Disease area, cancer: Yes (raises risk) · Disease area
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Phase: 2/3 (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Blinding: single (lowers risk) · Design
• Design: parallel (raises risk) · Design
• Disease area, neurology: Yes (raises risk) · Disease area
• Sponsor's past trials: 3 (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: no FAERS history (raises risk) · Drug's FDA history
• Number of arms: 2 (raises risk) · Design
• Collaborators: 1 (raises risk) · Design
• Keywords listed: 8 (raises risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Fluorescence Detection of Adult Primary Central Nervous System Tumors With Tozuleristide and the Canvas System NCT04743310 · started 2021 · scored riskier than 99% of active trials completed
• Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors NCT02372409 · started 2015 · scored riskier than 99% of active trials terminated
• Study of BLZ-100 in Pediatric Subjects With CNS Tumors NCT02462629 · started 2015 · scored riskier than 71% of active trials completed
• Non-Invasive Focused Ultrasound (FUS) With Oral Panobinostat in Children With Progressive Diffuse Midline Glioma (DMG) NCT04804709 · started 2021 · scored riskier than 89% of active trials terminated
• Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM) NCT01067469 · started 2010 · scored riskier than 96% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.